Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
Beta Drugs IPO is a fixed price issue of ₹19.52 crores. The issue is entirely a fresh issue of 0.23 crore shares of ₹19.52 crore.
Beta Drugs IPO bidding started from Sep 29, 2017 and ended on Oct 4, 2017. The shares got listed on NSE SME on Oct 12, 2017.
Beta Drugs IPO price is ₹85.00 per share . The lot size for an application is 1,600. The minimum amount of investment required by an individual investor (retail) is ₹1,36,000 (1600 shares). The minimum lot size investment for HNI is 2 lots (3,200 shares), amounting to ₹2,72,000.
Pantomath Capital Advisors Pvt.Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue. The market maker of the company is Pantomath Stock Brokers Pvt.Ltd..
Refer to Beta Drugs IPO RHP for detailed Information.
| IPO Date | September 29, 2017 to October 4, 2017 |
| Listing Date | October 12, 2017 |
| Face Value | ₹10 per share |
| Issue Price Band | |
| Issue Price Final | ₹85 per share |
| Lot Size | 1,600 Shares |
| Sale Type | Fresh Capital |
| Total Issue Size | 22,96,000 shares (aggregating up to ₹19.52 Cr) |
| Reserved for Market Maker | 1,29,600 shares Pantomath Stock Brokers Pvt.Ltd. (aggregating up to ₹1.10 Cr) |
| Net Offered to Public | 21,66,400 shares (aggregating up to ₹18.41 Cr) |
| Issue Type | Fixed Price IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 63,35,500 shares |
| Share Holding Post Issue | 86,49,500 shares |
Beta Drugs IPO offers total 22,96,000 shares. Out of which 10,83,200 (47.18%) allocated to NII, 10,83,200 (47.18%) allocated to RII.
| Investor Category | Shares Offered |
|---|---|
| Market Maker Shares Offered | 1,29,600 (5.64%) |
| NII (HNI) Shares Offered | 10,83,200 (47.18%) |
| Retail Shares Offered | 10,83,200 (47.18%) |
| Total Shares Offered | 22,96,000 (100.00%) |
Beta Drugs IPO opens on September 29, 2017, and closes on October 4, 2017.
| IPO Open Date | Fri, Sep 29, 2017 |
| IPO Close Date | Wed, Oct 4, 2017 |
| Tentative Listing Date | Thu, Oct 12, 2017 |
| Cut-off time for UPI mandate confirmation | 5 PM on Wed, Oct 4, 2017 |
Investors can bid for a minimum of 1,600 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 1,600 | ₹1,36,000 |
| Retail (Max) | 1 | 1,600 | ₹1,36,000 |
| HNI (Min) | 2 | 3,200 | ₹2,72,000 |
Beta Drugs Limited is pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers. Beta Drugs is primarily engaged in the manufacturing of oncology products. The products include anti-cancer tablets, capsules, injections and lyophilized injections. Company has portfolio of over 50 products which is used for the treatment of various cancer diseases.
Beta Drugs Limited is a part of Adley Group, which was founded in the year 1985. Company's manufacturing unit is located at Solan, Himachal Pradesh.
Company Strengths:
1. Focus on oncology segment. Manufacture over 50 products in this segment.
2. 18 product registrations in various countries. Company is in-process of making additional 12 applications for product registration in various countries.
The Company Beta Drugs IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
| S.No. | Objects of the Issue | Expected Amount (₹ in crores) |
|---|---|---|
| 1 | Purchase of new plant and machinery and upgradtion of the existing plant and machinery | 7.42 |
| 2 | Civil Construction work at existing manufacturing unit. | 1.28 |
| 3 | To obtain registration of European Union GMP & Pharmaceutical Inspection Co-operation Scheme | 0.79 |
| 4 | Working Capital | 2.95 |
| 5 | General Corporate Purpose | 4.10 |
[Dilip Davda] Considering reasonable pricing and prospects of healthcare industry going forward, investment may be considered for short to long term. Read detail review...
| Listing Date | October 12, 2017 |
| BSE Script Code | |
| NSE Symbol | BETA |
| ISIN | INE351Y01019 |
| Final Issue Price | ₹85 per share |
| Price Details | NSE SME |
|---|---|
| Final Issue Price | ₹85.00 |
| Open | ₹102.00 |
| Low | ₹92.00 |
| High | ₹102.00 |
| Last Trade | ₹101.95 |
Beta Drugs Ltd.
Village,
Nandpur
Baddi, Himachal Pradesh, 17410
Phone: 01795-236196
Email: info@betadrugslimited.com
Website: http://betadrugslimited.com/
MUFG Intime India Pvt.Ltd.
Phone: +91-22-4918 6270
Email:
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
Beta Drugs IPO is a SME IPO of 22,96,000 equity shares of the face value of ₹10 aggregating up to ₹19.52 Crores. The issue is priced at ₹85 per share. The minimum order quantity is 1600.
The IPO opens on September 29, 2017, and closes on October 4, 2017.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on NSE SME.
Zerodha customers can apply online in Beta Drugs IPO using UPI as a payment gateway. Zerodha customers can apply in Beta Drugs IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Beta Drugs IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Beta Drugs IPO opens on September 29, 2017 and closes on October 4, 2017.
Beta Drugs IPO lot size is 1600, and the minimum amount required for application is ₹1,36,000.
You can apply in Beta Drugs IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Beta Drugs IPO will be done on [.], and the allotted shares will be credited to your demat account by [.]. Check the Beta Drugs IPO allotment status.
The Beta Drugs IPO listing date is on Thursday, October 12, 2017.
Useful Articles
RHP